Dr. Basil S. Cherpelis, MD

Dr. Cherpelis practices at USFCenter for Advanced Healthcare in Tampa, Florida.

Dr. Cherpelis' NPI, 1124069398, was assigned on June 9, 2006. Dr. Cherpelis graduated from Jacobs School of Medicine and Biomedical Sciences in 1996. Dr. Cherpelis holds Florida license ME75479.

Dr. Cherpelis' primary practice is USFCenter for Advanced Healthcare, at 13330 Usf Laurel Dr, Tampa, FL 33612 in Hillsborough County. The practice phone is (813) 974-2201.

Dr. Cherpelis' primary practice is USFCenter for Advanced Healthcare in Tampa, Florida. The medical group on file is USF Therapy Services. Dmand AI also links Dr. Cherpelis to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cherpelis practices. Vendor and product names are available with a free account.

Mohs-micrographic surgery is Dr. Cherpelis' primary specialty in the NPI Registry, under taxonomy code 207ND0101X. Dr. Cherpelis is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Cherpelis' licenses on file in 2 states: Florida and South Carolina.

Dmand AI lists acne, benign or precancerous skin growths, cancerous skin growth removal, contact dermatitis, rash, scalp rash, skin cyst and skin discoloration among the conditions Dr. Cherpelis treats.

CMS data shows 5,404 Medicare services from Dr. Cherpelis across 31 procedure codes in 2024, for 739 Medicare patients. Medicare paid $701,520 for them. Every service was in an office.

CMS counts 739 Medicare patients who saw Dr. Cherpelis in 2024. The largest group is 65 to 74, with 318 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 3% are also on Medicaid. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cherpelis' median patient age at 74, with 45% women.

In 2024, Dr. Cherpelis wrote 559 Medicare Part D claims for 318 patients. 99% of them were for generic drugs. CMS names the drug for 468 of them, across 9 drugs with 11 or more claims each, at $8,539 in total drug cost. In 2023, CMS named 346 claims across 7 drugs.

Dr. Cherpelis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cherpelis as offering telehealth. CMS counts 210 procedures of melanoma (skin cancer) excision by Dr. Cherpelis, more than 97% of the clinicians it reports for that procedure.

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 54 papers to Dr. Cherpelis, published from 2009 to 2024. 2015 was the busiest year, with 4. The most frequent topics are Skin Neoplasms, Mohs Surgery and Melanoma. Dr. Cherpelis has published most often in Dermatol Surg. Dr. Cherpelis' most frequent co-authors are Jane L. Messina, MD, Vernon K. Sondak, MD and Brooke Taylor Baldwin, MD.

CMS Open Payments shows 3 general payments to Dr. Cherpelis from 3 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $116.

Dmand AI lists 1 award for Dr. Cherpelis.

Dr. Cherpelis graduated from Jacobs School of Medicine and Biomedical Sciences in 1996. Dr. Cherpelis is a member of ASDS.

Dr. Cherpelis is in network with 17 carriers, including Aetna, United Healthcare and Cigna. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.